The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review

Meyers, Brandon M.; Knox, Jennifer J.; Liu, David M.; McLeod, Deanna; Ramjeesingh, Ravi; Tam, Vincent C.; Lim, Howard John

doi:10.1016/j.ctrv.2023.102584

Cited by 5 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, the use of ICIs alone and in combination with other treatment modalities has proven to be an effective strategy for patients with advanced HCC. 16 , 17 However, there are clinical challenges in identifying patients who would benefit from ICIs therapy. To date, there are no effective biomarkers to predict the efficacy of ICIs therapy in patients with advanced HCC.…”

Section: Discussionmentioning

confidence: 99%

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients

Zhang,

Yin,

Tang

et al. 2024

JIR

View full text Add to dashboard Cite

Background Effective biomarkers are needed to predict the efficacy of immune checkpoint inhibitors (ICIs) therapy in hepatocellular carcinoma (HCC). We evaluated the early changes in serum interleukin-8 (IL-8) levels as a biomarker of response to ICIs in patients with unresectable HCC. Methods Eighty patients who received ICIs therapy alone or in combination with other treatments for unresectable HCC were included. Serum was collected at baseline and 2–4 weeks after the first dose. Serum IL-8 levels were measured using by ELISA. Results In the progressive disease (PD) group, serum IL-8 levels increased significantly before the second dose of ICIs therapy compared with baseline levels ( P < 0.001). Early changes in serum IL-8 levels were significantly associated with the response to ICIs therapy ( P < 0.001). A cutoff value of 8.1% increase over the baseline most effectively predicted the response to ICIs. Increases in serum IL-8 levels > 8.1% indicated the uselessness of ICIs immunotherapy in patients with unresectable HCC. Patients with increases in serum IL-8 levels > 8.1% had significantly shorter overall survival (OS) and progression-free survival (PFS) than those with increases in serum IL-8 levels ≤ 8.1% ( P < 0.001). Increases in serum IL-8 levels > 8.1% were independent prognosticators of worse OS ( P = 0.003) and PFS ( P < 0.001). Conclusion Early changes in serum IL-8 levels, measured only 2–4 weeks after starting therapy, could predict the response to ICIs therapy, as well as OS and PFS of patients with unresectable HCC. Increases in serum IL-8 levels > 8.1% indicated the uselessness of ICIs immunotherapy and predicted worse OS and PFS.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients

Zhang,

Yin,

Tang

et al. 2024

JIR

View full text Add to dashboard Cite

show abstract

“…Although sorafenib extends patient survival by only a few months, it helps to stabilize the tumor [5]. Recently, the combination of atezolizumab and bevacizumab has increased the number of available HCC treatment options [6][7][8]. However, new drug options are still urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Ru(II)-based complexes containing 2-thiouracil derivatives suppress liver cancer stem cells by targeting NF-κB and Akt/mTOR signaling

Bomfim,

Neves,

Coelho

et al. 2024

Cell Death Discov.

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are defined as a rare population of cancer cells related to tumor initiation and maintenance. These cells are primarily responsible for tumor growth, invasion, metastasis, recurrence, and resistance to chemotherapy. In this paper, we demonstrated the ability of Ru(II)-based complexes containing 2-thiouracil derivatives with the chemical formulas trans-[Ru(2TU)(PPh3)2(bipy)]PF6 (1) and trans-[Ru(6m2TU)(PPh3)2(bipy)]PF6 (2) (where 2TU = 2-thiouracil and 6m2TU = 6-methyl-2-thiouracil) to suppress liver CSCs by targeting NF-κB and Akt/mTOR signaling. Complexes 1 and 2 displayed potent cytotoxic effects on cancer cell lines and suppressed liver CSCs from HepG2 cells. Increased phosphatidylserine exposure, loss of mitochondrial transmembrane potential, increased PARP (Asp214) cleavage, DNA fragmentation, chromatin condensation and cytoplasmic shrinkage were detected in HepG2 cells treated with these complexes. Mechanistically, complexes 1 and 2 target NF-κB and Akt/mTOR signaling in HepG2 cells. Cell motility inhibition was also detected in HepG2 cells treated with these complexes. Complexes 1 and 2 also inhibited tumor progression in mice with HepG2 cell xenografts and exhibited tolerable systemic toxicity. Taken together, these results indicate that these complexes are new anti-HCC drug candidates that can suppress liver CSCs.

show abstract

Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles

Hsu,

Mustafa,

Kumar

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma – A systematic review

Cited by 5 publications

References 79 publications

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients

Changes in Serum Interleukin-8 Levels Predict Response to Immune Checkpoint Inhibitors Immunotherapy in Unresectable Hepatocellular Carcinoma Patients

Ru(II)-based complexes containing 2-thiouracil derivatives suppress liver cancer stem cells by targeting NF-κB and Akt/mTOR signaling

Exploiting the immune system in hepatic tumor targeting: Unleashing the potential of drugs, natural products, and nanoparticles

Contact Info

Product

Resources

About